Table 3.

Incidence rates and relative risks for COVID‐19‐related events and other outcomes in MS patients, compared with matched population‐based controls, March 1, 2020, through June 30, 2021.

Cohort	Outcome	Events, n	IR per 100,000 person‐years (95% CI)	HR (95% CI)
				Model 1	Model 2
MS	Death, any	284	3.34 (2.97–3.75)	2.55 (2.21, 2.94)	1.53 (1.31, 1.79)
	Death, COVID‐19	32	0.38 (0.27–0.53)	2.56 (1.67, 3.92)	1.88 (1.18, 3.02)
	Hospitalization, any	3,720	46.3 (44.8–47.8)	1.95 (1.88, 2.02)	1.40 (1.34, 1.46)
	Hospitalization, COVID‐19	336	3.97 (3.57–4.42)	2.91 (2.54, 3.33)	2.36 (2.04, 2.72)
	ICU admission, any	179	2.11 (1.82–2.44)	2.26 (1.89, 2.70)	1.48 (1.22, 1.80)
	ICU admission, COVID‐19	40	0.47 (0.34–0.64)	3.00 (2.02, 4.45)	2.92 (1.94, 4.40)
Controls	Death, any	544	1.31 (1.20–1.43)	Ref.	Ref.
	Death, COVID‐19	61	0.15 (0.11–0.19)	Ref.	Ref.
	Hospitalization, any	9,560	23.7 (23.3–24.2)	Ref.	Ref.
	Hospitalization, COVID‐19	565	1.36 (1.26–1.48)	Ref.	Ref.
	ICU admission, any	387	0.93 (0.84–2.11)	Ref.	Ref.
	ICU admission, COVID‐19	65	0.16 (0.12–0.20)	Ref.	Ref.

Model 1: Adjusted for age, sex, region, and time from start of each pandemic wave.

Model 2: Further adjusted for country of birth, education, civil status, comorbidities, n of hospital days the previous year, n of hospital days previous 10 years.

CI, confidence interval; HR, hazard ratio; IR, incidence rate; MS, multiple sclerosis.